XML 46 R30.htm IDEA: XBRL DOCUMENT v2.4.1.9

Collaboration Revenue (Tables)

3 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summarized Collaboration Revenues

The following table summarizes the amounts recorded in the consolidated statements of income for each significant collaboration for the three months ended March 31, 2015 and 2014.

	Three Months Ended March 31, 2015
	Collaboration Revenue Recognized From								Total
	Upfront and Milestone Payments				Research and Development Services
ZIOPHARM Oncology, Inc.	$	644			$	3,157			$	3,801
Oragenics, Inc.	262				8				270
Fibrocell Science, Inc.	448				1,713				2,161
Genopaver, LLC	69				600				669
S & I Ophthalmic, LLC	—				755				755
OvaXon, LLC	—				644				644
Intrexon Energy Partners, LLC	625				2,185				2,810
Persea Bio, LLC	125				115				240
Other	858				2,527				3,385
Total	$	3,031			$	11,704			$	14,735

	Three Months Ended March 31, 2014
	Collaboration Revenue Recognized From								Total
	Upfront and Milestone Payments				Research and Development Services
ZIOPHARM Oncology, Inc.	$	644			$	2,036			$	2,680
Oragenics, Inc.	262				533				795
Fibrocell Science, Inc.	448				862				1,310
Genopaver, LLC	69				421				490
S & I Ophthalmic, LLC	—				879				879
OvaXon, LLC	—				169				169
Other	459				1,055				1,514
Total	$	1,882			$	5,955			$	7,837

Summary of Deferred Revenue

Deferred revenue consists of the following:

	March 31, 2015				December 31, 2014
Upfront and milestone payments	$	104,297			$	107,228
Prepaid research and development services	1,038				1,045
Prepaid product and service revenues	4,740				4,365
Other	1,212				571
Total	$	111,287			$	113,209
Current portion of deferred revenue	$	17,289			$	16,522
Long-term portion of deferred revenue	93,998				96,687
Total	$	111,287			$	113,209

X

- Definition

Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765



Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueByArrangementDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of summarized revenues recognized for each significant collaboration and aggregated nonsignificant collaborations.

+ References

No definition available.

+ Details

Name:	xon_CollaborationRevenuesTableTextBlock
Namespace Prefix:	xon_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration